SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (2 shown)

Not Yet RecruitingPhase 2

NCT05402384

AVTX-801 D-galactose Supplementation in SLC35A2-CDG

This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-C…

United States10 participantsStarted 2027-01

Treatment: AVTX-801, Placebo

UnknownNot Applicable

NCT04833322

Galactose Supplementation for the Treatment of MOGHE

Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new entity frequently associated with refractory epilepsy a…

Spain8 participantsStarted 2021-01-15

Treatment: D-Galactose